Project Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Treatment of autism spectrum disorders with a glutamate antagonist  

The study is a 12-week, placebo-controlled investigation of the safety and efficacy of riluzole for the treatment of obsessive-compulsive symptoms among 30 children and adolescents (ages 7 to 17 years) with autism spectrum disorder (ASD) and obsessive-compulsive disorder (OCD).


Funder National Institutes of Health
Fiscal Year Funding $465,840.00
Project Number Z01MH002913-01
Principal Investigator Swedo, Susan
Strategic Plan Question Question 4: Which Treatments And Interventions Will Help? (Interventions)
Strategic Plan Objective Green dot: Objective has greater than or equal to the recommended funding. 4.7 Complete two multi-site randomized controlled trials of comprehensive early intervention that address core symptoms, family functioning and community involvement by 2013. IACC Recommended Budget: $16,700,000 over 5 years.
Federal or Private? Federal
Institution National Institutes of Health
State/Country Maryland
Web Link 1 No URL available.
Web Link 2 No URL available.
Web Link 3 No URL available.
History/Related Projects Treatment of autism spectrum disorders with a glutamate antagonist | $203,517.00 | 2009 | 1ZIAMH002913-02